ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

AbbVie (ABBV) announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases to AbbiVie’s Immunology pipeline. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics.Nimble’s lead p ...